PCSK9 and type 2 diabetes mellitus: Consistent with this meta-analysis, our study did not observe any significant changes in HbA1c levels over the course of treatment, affirming the metabolic safety and tolerability of PCSK9 inhibitors in patients with pre-existing T2DM.